Mixed Results in NSCLC, SCLC Trials (CME/CE)
(MedPage Today) -- Two-thirds of patients with recurrent, mutated non-small cell lung cancer responded to an investigational agent that selectively targets mutant cells and spares normal ones, results of a preliminary trial showed.
Source: MedPage Today Geriatrics - Category: Geriatrics Source Type: news
More News: Cancer | Cancer & Oncology | Geriatrics | Lung Cancer | Non-Small Cell Lung Cancer | Small Cell Lung Cancer